NASDAQ : NRSN
NeuroSense Therapeutics Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 1.99 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.64M |
| Enterprise Value | 2.65M |
Dates
| Measure | Value |
|---|
| Earnings Date | Sep 25, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.85M |
| Shares Outstanding | 1.85M |
| Shares Change (YoY) | +36.98% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 32.47% |
| Owned by Institutions (%) | 1.15% |
| Float | 1.25M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 7.16 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.31 |
| Quick Ratio | 0.08 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -2,174.98% |
| Return on Assets (ROA) | -247.30% |
| Return on Invested Capital (ROIC) | -1,094.49% |
| Return on Capital Employed (ROCE) | 744.96% |
| Weighted Average Cost of Capital (WACC) | 12.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$654,412 |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.64 |
| 52-Week Price Change | -93.79% |
| 50-Day Moving Average | 5.32 |
| 200-Day Moving Average | 12.78 |
| Relative Strength Index (RSI) | 17.83 |
| Average Volume (20 Days) | 42,525 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 26,105 |
| Short Previous Month | 26,883 |
| Short % of Shares Out | 1.41% |
| Short % of Float | 2.09% |
| Short Ratio (days to cover) | 1.13 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.09M |
| Pretax Income | -11.13M |
| Net Income | -11.13M |
| EBITDA | -11.07M |
| EBIT | -11.09M |
| Earnings Per Share (EPS) | -$8.73 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 166,000 |
| Total Debt | 170,000 |
| Net Cash | -4,000 |
| Net Cash Per Share | -$0.00 |
| Equity (Book Value) | -1.56M |
| Book Value Per Share | -0.96 |
| Working Capital | -1.74M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -7.67M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 16,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.68M |
| FCF Per Share | -$4.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -36.98% |
| Shareholder Yield | -36.98% |
| Earnings Yield | -610.62% |
| FCF Yield | -208.74% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $91.75 |
| Price Target Difference | 6,316.08% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 14, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |